Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Germline predictors of recurrence in patients with ER-positive and HER2-negative breast cancer: A GWAS analysis of multiple cohorts totaling 10,640 patients
Presenter: Emma Turcotte
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - The role of systemic immunity in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - Development of an exo-miRNA panel for metastasis prediction in breast cancer
Presenter: Shafiqa Siddique
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - Molecular characterization of circulating tumor cells in metastatic breast cancer using shallow whole genome sequencing
Presenter: Michela Bulfoni
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Single-cell transcriptomic and cell-cell communication profiles in breast cancer responders to chemotherapy or chemo-immunotherapy
Presenter: Marcela Carausu
Session: Cocktail & Poster Display session
Resources:
Abstract
20P - Distinctive genomic profile of lymph node profile and distant metastasis in papillary thyroid cancer
Presenter: Sara Gil-Bernabé
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Improving early cancer screening efficacy by adjusting tumor burden spectrum bias of liquid biopsy biomarkers
Presenter: Weituo Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Comparative analysis of miRNA biomarkers in liquid-based cytology and plasma for early detection of high-grade cervical intraepithelial neoplasia
Presenter: Stéphanie Calfa
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Unraveling predictive transcriptomic signatures of anti-EGFR therapy response in RAS/BRAF wild-type metastatic colorectal cancer
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - Integrated proteogenomic approach for discovering potential biomarkers in urothelial carcinoma of the bladder
Presenter: PONGSAKORN CHOOCHUEN
Session: Cocktail & Poster Display session
Resources:
Abstract